Boston Scientific announced a $1.5 billion investment to acquire an approximate 34% equity stake in MiRus, strengthening its position in the transcatheter aortic valve replacement (TAVR) market.

As part of the agreement, Boston Scientific secured an exclusive option to acquire MiRus’ TAVR business through additional milestone-based payments and regulatory achievements.

The investment centers on the SIEGEL Balloon Expandable TAVR system, a next-generation valve platform developed to restore blood flow in patients suffering from severe aortic stenosis. The SIEGEL valve is described as the first nickel-free, balloon-expandable TAVR valve built using a proprietary rhenium alloy technology.

MiRus recently initiated the STAR pivotal trial to evaluate the safety and effectiveness of the SIEGEL valve across up to 1,025 patients with severe symptomatic aortic stenosis across varying surgical risk categories. The company also presented positive early feasibility study data for the technology last year.

Under the agreement's terms, Boston Scientific may acquire full ownership of MiRus’ TAVR business for an additional $3 billion upon achievement of specified clinical and regulatory milestones. MiRus may also receive additional payments linked to future net sales of the SIEGEL TAVR valve.

Lance Bates, Executive Vice-President and President, Interventional Cardiology and Vascular Therapies, Boston Scientific, said, “The occurrence and recognition of aortic stenosis is growing rapidly, and our investment in MiRus continues our pursuit to bring a differentiated TAVR system into our portfolio that we anticipate may improve outcomes for patients living with this life-threatening disease.”